The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | BCL-2 inhibitors: the current landscape
BCL-2 inhibitors like ibrutinib and venetoclax have been used in the treatment of lymphoproliferative disorders like chronic lymphocytic leukemia (CLL) for long enough that mid-term effects of the agents can be analyzed. In this interview, Francesco Forconi, MD, DM, PhD, FRCPath, from the University of Southampton, Southampton, UK, discusses what we know at this stage at the 23rd Congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Results are promising for using these molecules, either as single agents or in combination with anti-CD20 antibodies or BTK inhibitors.
